You are Here
JB Chemicals & Pharmaceuticals Ltd (JB) Reports Revenue growth of 10% in Q3 FY22 to INR 601 crores
Business

JB Chemicals & Pharmaceuticals Ltd (JB) Reports Revenue growth of 10% in Q3 FY22 to INR 601 crores

4 min read

As per IQVIA, JB was the fastest-growing company among the top 30 companies for CY 2021

Mumbai (Maharashtra), February 15: J. B. Chemicals & Pharmaceuticals Limited (JB), one of the fastest-growing pharmaceutical companies in India, announced its financial results for the third quarter ended 31st December 2021.

For the third quarter ended 31st December 2021, the company recorded revenue of INR 601 crores compared to INR 548 crores, registering a growth of 10% over the corresponding quarter of the previous financial year. Comparing Q3 FY22 versus Q3 FY21 shows underlying revenue growth for Q3 FY22 was 23% (After excluding revenue deferred to Q3 FY21 from Q2 FY21), and operating EBITDA* (Earnings Before Interest Depreciation and Taxes) were conservative at INR 153 crores as compared to INR 171 crores. Profit after Tax stood at INR 84 crores compared to INR 154 crores attributed to one-off income due to trademark sale in Q3 FY21 (~ INR 34 crores), higher treasury income in Q3 FY21, revenue deferment to Q3 FY21 and non-Cash ESOP charge in Q3 FY22.

Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, said, “Our performance in the third quarter reflects a strong business momentum in a macroeconomic environment that has continued to be challenging. Revenue growth in India saw positive traction from our renewed Go-To-Market model and product introductions resulting in JB maintaining its position as the fastest-growing company among the Top-30 in the industry^. Further, major parts of our international business, including CMO, witnessed a gradual revival of demand. Our margins reflect the significant increase in raw materials costs and persistent supply chain-related challenges. Going forward, we will maintain focus on driving topline growth, cost optimization and organizational efficiencies.”  He further added, “We see multiple levers for outperformance – leveraging our existing Go-To-Market model strength, maximizing new introductions & lifecycle management opportunities and strengthening our international markets through portfolio augmentation. The acquisition of the brand portfolio from Sanzyme will further strengthen our domestic business and improve our market position. All these initiatives should translate into enhanced long-term value for all our stakeholders.”

^ As per IQVIA MAT Dec 21 data

Financial Performance – 9M FY22 vs 9M FY21

For the nine months of the financial year 2021-22, the company recorded revenue of INR 1800 crores compared to INR 1514 crores, registering a growth of 19%. Operating EBITDA* (Earnings Before Interest Depreciation and Taxes) increased by 5% to INR 457 crores compared to INR 437 crores. Adjusted EBITDA** increased by 8% to INR 471 crores. Profit after Tax stood at INR 301 crores compared to INR 348 crores, registering a decline of 13 %.

*Operating EBITDA is after excluding non-cash ESOP Charge

**Adjusted EBITDA after excluding non-cash ESOP Charge and one-time non-recurring expense

Revenue momentum remained strong despite the challenging operating environment in the third quarter. Excluding the revenue, which got deferred to Q3 FY21 from Q2 FY21 in the previous financial year, the sales growth for Q3 FY22 was 23%. The Gross Margin profile remains steady at 66% in Q3 FY22. Significant inflation witnessed in API prices, managed through cost optimization initiatives and price increases. Operating costs are now at normalized levels, excluding ESOP charge, employee benefits expense increased by 11%. Other expenditures witnessed a sharp increase in Q3 FY22, led by a significant escalation in logistics/freight costs and a substantial increase in Power & Fuel costs.

Domestic Formulations business continues its good performance growing at 20% in Q3 FY22 vs Q3 FY21. As per IQVIA, JB was the fastest-growing company among the top 30 companies for CY 2021, and as per MAT Dec 2021, JB grew at 27% vs market growth of 18%. Re-aligned Go-To-Market model continues to deliver positive results w.r.t. productivity improvement and new introductions. New Products contributed 4.2% to Domestic sales in Q3 FY22 and 4% for 9M FY22. During Q3 FY22, the Domestic Formulations business launched 12 new products, including Molnupiravir, Cilacar TM, Azovas-T and Pirfenidone. Cost pressure persists on raw material and packing material; this is expected to continue in the medium-term.

International business revenue grew at 3% in Q3 FY22 vs Q3 FY21, showing sequential improvement in international business, and underlying growth for Q3 FY22 is higher than the reported number due to deferment of revenues from Q2 FY21 to Q3 FY21. International business further witnessed steady revival except for the US business. South Africa continues to record growth in both public and private markets. Russia/CIS region delivered strong growth for Q3 FY 22. CMO business performed well due to demand revival in key markets. Supply chain disruptions and higher freight costs remain a challenge, as freight costs increased significantly for all key markets.

Share
Facebook Twitter Pinterest Linkedin

Related Posts

129 thoughts on “JB Chemicals & Pharmaceuticals Ltd (JB) Reports Revenue growth of 10% in Q3 FY22 to INR 601 crores”

  3. Magnificent beat ! I wish to apprentice at the same time as you amend
    your website, how could i subscribe for a weblog website?

    The account helped me a acceptable deal. I have been a
    little bit familiar of this your broadcast offered vibrant clear idea

  4. Do you mind if I quote a couple of your articles as long as I provide
    credit and sources back to your website? My blog site is in the very same niche as yours and
    my visitors would definitely benefit from a lot of the information you present here.

    Please let me know if this alright with you. Regards!

  8. Does your site have a contact page? I’m having trouble locating
    it but, I’d like to send you an e-mail. I’ve got some recommendations for your blog you might be interested in hearing.
    Either way, great blog and I look forward
    to seeing it improve over time.

  12. Hi there, just became alert to your blog through Google,
    and found that it’s really informative. I’m going to watch out for brussels.
    I will be grateful if you continue this in future.
    Lots of people will be benefited from your writing. Cheers!

  13. Do you have a spam issue on this blog; I also am a
    blogger, and I was wanting to know your situation; we have created some
    nice practices and we are looking to exchange strategies with other folks,
    why not shoot me an e-mail if interested.

  16. Hi, I think your site might be having browser compatibility issues.
    When I look at your website in Chrome, it looks fine but when opening in Internet Explorer, it
    has some overlapping. I just wanted to give you a quick heads up!
    Other then that, great blog!

  17. Hi! This is my 1st comment here so I just wanted to give a quick
    shout out and say I truly enjoy reading your posts.
    Can you recommend any other blogs/websites/forums that
    deal with the same subjects? Thank you!

  18. I absolutely love your blog and find nearly all of your
    post’s to be what precisely I’m looking for. can you offer guest writers to write content available for you?
    I wouldn’t mind producing a post or elaborating on many of the subjects you write about here.
    Again, awesome site!

  19. Hello there, just became aware of your blog through Google, and found that it is really informative.
    I’m gonna watch out for brussels. I’ll appreciate if
    you continue this in future. Lots of people will be benefited from your
    writing. Cheers!

  83. Commonly Used Drugs Charts. Long-Term Effects. [url=https://amoxicillins.online/]cost of amoxicillin 875 mg[/url]
    Actual trends of drug. Read information now.

  88. Learn about the side effects, dosages, and interactions. drug information and news for professionals and consumers.
    drugs for ed
    Actual trends of drug. Best and news about drug.

  123. drug information and news for professionals and consumers. Best and news about drug.
    https://tadalafil1st.com/# cialis 20 mg from united kingdom
    Medscape Drugs & Diseases. Learn about the side effects, dosages, and interactions.

Leave a Reply

Your email address will not be published.

Mail us : info@justnewsnow.com